SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?


To: gao seng who wrote (437)6/15/2000 8:30:00 PM
From: allen menglin chen  Read Replies (1) | Respond to of 746
 
A nice Fools post about genome size of diff spices. Human is not "smart" if u judge from the genome size :)
===========================================================
This is what I like about the CRA board and TMF in general. Everyone thinks they are an expert, and we all are on some subject, but we can still exchange ideas in a civil manner and try to learn something from each other!

Well, as my not-so-innocent comment on "junk DNA" ( boards.fool.com spawned some 25 posts, I guess there's enough interest in the subject for me to put a little effort into a response. Actually, in the process I learned a few things myself!

Here's my inflammatory statement again:'Incidentally, for those of you convinced that the so-called "junk DNA" is actually a gold mine waiting to be discovered, he [referring to Sydney Brenner, a famous scientist] also has a pretty definitive argument as to why it really is "junk". But I'm saving that for the next time that discussion comes up.'

My basic point is that I think a lot of CRA investors feel that (and Venter encourages this) the 97% of the genome that is classified as "junk DNA" is comparable in value to biomedical research as the 3% that is present in INCY's and HGSI's databases. Well it isn't. Sorry to let you down. ;) Some fraction of it is clearly valuable, some of it may someday turn out to have value, but the overwhelming bulk really is JUNK. This is not my pet theory, but is pretty well accepted in the field of genomics, especially by bright guys like Venter. It's just not in CRAs interest to say this too loudly. [Besides HGSI's Haseltine say's it often enough!]

What I'm going to say here shouldn't by itself cause you to question the value of CRA as an investment. But the more you understand about your investment the better position you will be in to judge its future prospects.

Anyway, to start off, let's define "junk DNA." Despite sounding like a catch phrase dreamed up by a writer for Time magazine, this is actually a term that is in wide use in the genomics field. It is based on the current belief that approximately 3% of the human genome represents genes that "code" for proteins. Remember that old DNA makes RNA which makes (codes) for proteins idea. The rest of the genome, 97%, doesn't code for proteins. [Actually, this 3% number is a guesstimate, and you hear other numbers quoted sometimes. But give or take a few percent, it's probably fairly accurate.]

What is the remaining 97% thought to be good for?

Well some of it, as JefOfool pointed out ( boards.fool.com ), are the "regulatory elements" that turn the protein-coding genes on and off. These bits of DNA, usually next to the coding genes, are what determine that your eyes produce eye proteins and not liver proteins, and visa versa. They are what turns insulin production on and off in response to your eating a meal. Obviously VERY important. Actually, I've spent 2/3s of my career as a scientist working on these bits of DNA, so I'll be the last to argue that they are not important.

To the best of our current knowledge, the average amount of DNA involved in regulating a particular gene is approximately the same amount of DNA as that coding for the protein. This is a gross generalization, but a gene of 5000 basepairs (remember the human genome is 3 billion basepairs) of DNA might have another 1000, 5000 or maybe more basepairs of DNA that turns it on and off. Although some genes are 1 million basepairs long, their regulatory elements might still only be several thousand basepairs in size. Some tiny genes have regulatory elements bigger than the genes themselves. The bottom line is that, as a crude approximation, these regulatory elements might make up another 3% of the genome. Perhaps it is only 0.5% or as high as 6%, but 3% is close enough for this discussion.

So now we're up to 6% of the genome that is "important." What's left? Well there are other types of regulatory elements that don't control genes but do play important functions (things like telomeres and cetromeres and other stuff I won't bore you with). However, these elements make up a very tiny fraction of the genome (I can't put a number on it, but it is small).

While we are talking about regulatory elements, let's discuss what they might be useful for from a biomedical standpoint. After all, CRA & HGP are providing us 10s of thousands of new regulatory elements to look at (actually they are not easy to recognize in the sequence, but they are there somewhere). There are clearly some applications that this type of information can be used for today. But that is dwarfed by the value of the coding genes themselves. This may not be true in 10 or 25 years, but it is today. One example of work being done in this area is Tularik, a biotech company that recently IPOed. They focus on developing small molecules drugs that specifically affect the control of genes via these regulatory elements. So far the results of this approach haven't reached the clinic, but it is still the early days for them. Along the same lines, my own company recently announced a drug discovered by this same strategy. Gene therapy is another possible application for this information. But as we all know that field still has a LOT of growing pains to go through.

Anyway, that 3% of control elements has some potential value yet to be realized, and obviously we wouldn't have access to it without the sequencing efforts of CRA and HGP.

What's left now? Try this on for size: an amazing 30% of our genome is squandered on "retrotransposed" sequences. This is what happens when a gene makes an RNA, which is then accidentally converted back into DNA and stuck back into the genome in a non-functional way. These sequences can also be remnants of ancient retroviruses that infected our ancestors. One class of these, called Alu elements, is represented in some 300,000 copies in our genome (compared with 50-100,000 real genes). One of these "retrotransposition" events is estimated to occur once in the lifetime on one in every 100 people. As JD said, "?our junk DNA does indeed contain many remnants of our evolution?" It doesn't sound like much, but over millions of years that results in 30% of our genome being this sort of JUNK.

Anything else? Well there are odds and ends like the non-functional "pseudogenes" that JD alluded to (post 15191), but I can't put a number on these (possibly several percent). So let's say that we've accounted for 6% functional and 30+% useless. That leaves a lot for CRA investors to get excited over! However, working in this field I've seen the sequence of most of this remaining "junk DNA" and I can't say I'm that excited. Sounds egotistical, doesn't it?

Here we arrive at an argument that several of you put forth. 1946dodge put it best:

'Just because we don't know what the "junk" is for, doesn't mean it has no purpose. I cannot conceive of anything as complex as life having random or unnecessary information coded into it. That would be absurd. God doesn't put things there that have no purpose. I have never heard Venter say that this stuff is useless random information. A real scientist would say: We have a large part of the genome that we do not understand YET. One of the critical mistakes scientists make is to assume something about which they know nothing about. It is an arrogant and fruitless attitude for any scientist to have. Many discoveries go on languishing unexplored because of this behavior in "experts". NO one is an expert until all the stuff makes sense. That may take a very long time, but mankind will hopefully be here longer."

Actually, 1946doge, this is a common trap both for scientists and non-scientists. Einstein himself refused to believe quantum mechanics basically because it didn't make sense at the "gut instinct" level. As current research is demonstrating, it may not make sense, but it is true. I hate to think about all the Science and Nature papers I missed out on writing, but someone else didn't, because I was so sure I "knew" how things worked. However, you are also falling into the same trap. Just because you can't imagine that functionless things exist, doesn't mean there are not lots of functionless things around. There are. As Spinality said, there are vestigial structures all over the place. Your appendix and tail bone are two trivial examples that are commonly mentioned. Sure, an appendix might have a function we don't know about. But a lot of people die from appendicitis, whereas I've never heard of someone dying from lack of an appendix. Doesn't sound like it should be selected for during evolution to me.

However, more to the point of our current discussion, lets talk about Nature's own evidence that tells us that most of the genome has little or no function. This is where Sydney Brenner (SB) comes in.

karljon wrote: "Here's another way of looking at it. Simple systems tend to have more stream-lined genomes. I know this is a gross generalization but, for the sake of argument, it works. The genome of an amoeba is not as complex as that of the human."

So, in other words (I'm good at putting words in people's mouths!), let's hypothesize that there is a direct correlation between the complexity (or more amusingly, the intelligence) of an organism and its genome size. Obviously this makes intuitive sense. We're bigger, smarter, and more complex than a single-celled amoeba swimming around in its little pond. This is how science works: we hypothesize and then we test our hypothesis.

Here's some actual numbers on the size of various genomes for our little thought experiment (note these are approximations). You'll have to take my word for it that this is not an exercise in data mining!

Species Genome size

Human 3,000,000,000 DNA basepairs (We all new that number!)

Cow 3,651,500,000 (Maybe your dinner was smarter than you thought? But at least it's a mammal like us.)

Chicken 1,200,000,000 (Pretty good for such a DUMB animal!)

Carp 1,700,000,000 (That makes sense. Carp are pretty dumb too.)

Zebrafish 1,900,000,000 (JD's favorite model, which CRA will sequence)

C. elegans 100,000,000 (The first fully sequence animal, an almost microscopic worm)

Fruit fly 180,000,000 (Well, obviously a fly is more complex than a worm with only 1000 cells. But wait, the big surprise is that CRA says the fly has fewer genes than the worm, despite its greater complexity and larger genome. That's weird!)

House fly 900,000,000 (I guess that makes sense. At least it's bigger; probably smarter too. I still don't get that worm thing.)

Rice 400,000,000 (Insects and plants. Yeah, they're both pretty dumb.)

Tomato 655,000,000 (Yawn? Ever seen "Attack of the Killer Tomatoes"?)

Soybean 1,115,000,000 (Hmm?pretty smart plant. Almost a chicken's IQ. Must be all that inbreeding.)

E. coli 4,639,221 (Lives in our guts. Fully sequenced 2 years ago.)

HIV-1 9,750 (Given how nasty it is, I'd have thought it was bigger.)

OK, so what's the big deal? Most of that makes sense doesn't it? Well, here's a little more:

Warty newt 20,600,000,000 (I hate to tell you guys, but a Warty newt has a lot more DNA than you!)

Corn 5,000,000,000 (Even worse, so does corn!)

Paramecium A 8,600,000,000 (The one-celled denizen of pond scum from high school biology.)

Paramecium B 190,000,000 (Smaller? That's more like it! But they look the same to me.)

Onion 18,000,000,000 (The next time someone calls you a vegetable, take it as a complement!)

Salamander 81,300,000,000 (Damm!)

Lungfish 139,000,000,000 (What the hell's a lungfish?)

Fern 160,000,000,000 (I'm starting to get pissed!)

And the winner is:

Amoeba 670,000,000,000 (A mere 200X more DNA than your or I, all in one cell.)

Well, surprising as it sounds, the largest known genome is actually an amoeba!!! Great call karljon!!!

What does this all mean? It means that the size, complexity (and number of genes as I discuss below) has nothing to do with the size of the genome.

Now Sydney Brenner and the Pufferfish (that famous Japanese delicacy).

As I mentioned, Sydney is a living scientific god. JD will be interested to know that the C. elegans worm that biotechs like Exelexis and all those academics perform functional genomics on was developed as a model organism single-handedly by SB. He was already a Nobel candidate prior to this. He must be about 80 years old now, but for the last several years he has been championing the Pufferfish genome project. Why? Well not because he likes sushi, but because Pufferfish have two interesting attributes. One, it's a vertebrate (has a spinal cord) like humans, and two, its genome is only 400 million basepairs long. Which as we now know is really TINY.

Well, besides being a really quick sequence for CRA, what's so interesting about that? Well for one, based on the sequencing that SB's done already, Pufferfish have the same number of genes as human, give or take a few. Not just the same number, the same genes, period. After all, they're vertebrates. So do mice and frogs and all the rest. They have most of the same organs as we do, and thanks to all the work done on Zebrafish (a popular genetic model in academia), we know that most of their fundamental processes are very similar to ours. But yet they get by with only 1/8th the amount of DNA we have! In fact, when SB sequences their DNA, what he finds is that pretty much all that remains are the genes and their regulatory elements. That 6% or so plus some other stuff that we talked about above. Most of the "Junk DNA" is gone. But it's still a pretty happy little fish. [This is why sequencing the Pufferfish is so important in SB's mind. Because its sequence is more diverged from human than mouse, and because all that's left is the important stuff, a comparison between human and Pufferfish can be used to rapidly identify all those "regulatory elements" we were talking about. The mouse, fly, worm, and Zebrafish can't do that.]

Well, draw you own conclusions. But I'm here to tell you that the genomics field thinks this means that most (not all, but most) of our "junk DNA" really is JUNK. We even have theories about why this is so. [Of course, that junk is a source of SNPs, though SNPs within genes are still more valuable than SNPs within junk DNA.]

Again, this is not an argument that sequencing the genome is a waste time. It's not. It's our generations Kitty Hawk or Tranquility Basin. But I do think it's a good idea for an investor to be able sift the strands of truth out of the tales Collins, Venter, Scott and Haseltine spin for us. And these are my 2 cents worth towards that end.

Fushi

P.S. Ken, you can make your witty rejoinder now.

boards.fool.com



To: gao seng who wrote (437)6/17/2000 12:12:00 AM
From: allen menglin chen  Respond to of 746
 
Charlie Rose Special Edition: Mapping the Human Genome
Business Wire - June 16, 2000 18:16

NEW YORK--(ENTERTAINMENT WIRE)--June 16, 2000--The human genome is referred to in the scientific community as the book of human life.

The race is on to decipher this complex book and the stakes are huge. This week, Charlie Rose explores the scientific and ethical issues surrounding "Mapping the Human Genome" in a fascinating series of interviews spotlighting the key players in what many believe will be one of the greatest achievements of our time.

Charlie Rose airs weeknights at 11:00 p.m. on PBS (check local listings)


Monday, June 19: Dr. Craig Venter, Chairman and Chief Scientific
Officer, Celera Genomics

Tuesday, June 20: Dr. Francis Collins, Director, National Human
Genome Research Institute

Wednesday, June 21: Dr. James Watson, President, Cold Spring Harbor
Laboratory; Dr. Harold Varmus, President & CEO,
Memorial Sloan-Kettering Cancer Center;
Arnold Levine, President and Heilbrunn Professor
in Cancer Biology, Rockefeller University;
Dr. Savio Woo, President, American Society of Gene
Therapy

Thursday, June 22: William Haseltine, CEO and Chairman, Human Genome
Sciences, Inc.; Viren Mehta, Managing Partner,
Mehta Partners Global Healthcare Investments;
Nicholas Wade, Science Writer, The New York Times;
Richard Preston, Author/Contributor New Yorker
magazine; Dr. Arthur Caplan, Director, Center for
Bioethics, University of Pennsylvania

Friday, June 23: Implications for the Future

CONTACT: Thirteen/WNET, New York
Kellie Specter, 212/560-3009
specter@thirteen.org

marketwatch.newsalert.com



To: gao seng who wrote (437)6/17/2000 12:06:00 PM
From: allen menglin chen  Read Replies (1) | Respond to of 746
 
Find a good Sydney paper hyping the coming genome news. BTW, I luv your "excite" search. Venter has been keeping investors/daytraders to buy CRA on dips the past few weeks. Now one Monday in June becomes the last Monday in June? It's only 9 days away, don't sell your CRA -- yet. :)
Why BBC, Sydney news sources claim to know the exact date the BIG news will drop?! Does CRA have a rumor dept?

smh.com.au
Has the genome been overhyped?

Date: 16/06/2000

A rough draft of the entire human genetic code - genome - has been completed, a milestone in the biggest scientific race since the drive to put a man on the Moon.
This "book of life", to be unveiled on June 26, will transform society. It could mark the start of a Brave New World of designer babies, gene therapy and genetic
underclasses. Two distinguished British commentators, Matt Ridley and Steve Jones, disagree about the genome's significance.

No - it's not been overhyped, argues MATT RIDLEY

With an enthusiastic book out about the genome, I am not just contributing to the genome hype. I might even be said to have a vested interest in it. Before I
started my book, nearly three years ago, I thought the Human Genome Project was going to make a big difference to biology. After a few months in the library
and on the internet, I had changed my mind: the Human Genome Project is going to make a gigantic difference, and not just to biology. It really is BIG NEWS.

As metaphors go, the gold mine is a tired cliche, but it can be refreshed by making it literal. Scientists are a bit like gold miners, the gold they seek being
nuggets of new knowledge. Some of the mines they dig are disappointing; some start well but are soon exhausted; others prove unexpectedly productive.

On this scale, the gold strike made by James Watson and Francis Crick on February 23, 1953 - that genes are things that store biochemical instructions in a
simple, duplicate, linear digital form - has proved to lead to the richest gold mine of all. In the intervening 50 years, scientists have been hard at work sinking
the mine. Now, this month, they begin production in earnest.

The human genome contains a universe of new information to explore and understand. Take just one example. From 1872 to 1993, virtually nothing was
known about Huntington's disease except that it ran in families. In 1993, the responsible gene was discovered. Since then, more than 100 scientists in more
than 20 countries have published new insights into what the gene does, how it goes wrong and what might be done to cure Huntington's. Even a summary of the
studies stretches to hundreds of pages.

And that is just one gene. There are at least 30,000 more, possibly four times as many. Ten years ago, only a handful were known. A year ago, only a few
thousand were known. Within weeks, they will all be known. In just a few months we have gone from striking a match in one corner of a cathedral to
switching on the floodlights.

The medical implications are immense. I have watched over his shoulder as an Italian scientist logs on to the internet to read from a Cambridge data base the
newly sequenced part of a human chromosome where he thinks there lies a gene that can predispose people to kidney stones. What would before have been
several years' work is now a few clicks of a mouse.

The completion of the genome will transform the prediction, prevention, treatment and understanding of disease. Its greatest possibilities lie in the field of
cancer, a disease caused exclusively by misbehaving genes. But it will affect ailments from depression to heart attacks.

Some are impatiently asking why this has not yet happened, which is a bit like a child saying, "Are we there yet?" 10 miles into a long journey. Proving that
treatments are safe and effective takes many years, so the flood of new diagnostic tests and drugs now being developed will not be in your local hospital
tomorrow. But 20 years hence, medicine may be unrecognisable.

Craig Venter, the man who has almost single-handedly brought this revolution forward from the distant future and forced it to happen this month, puts it more
pithily: "With this technology we are literally coming out of the dark ages of biology. As a civilisation, we know far less than one per cent of what will be
known about biology, human physiology and medicine. My view of biology is, "We don't know s---.' "

The medical applications matter desperately - and anybody who has watched a friend die of cancer will see the urgency of pressing ahead, rather than
tip-toeing cautiously - but they are not even the biggest ones. Nor are the ethical implications. It is true that genetic knowledge opens new possibilities for
tampering with nature, for transforming health insurance for the worse and for invading privacy. Vital as they are, none of these is qualitatively different from
the ethical dilemmas we face today.

What for me is more important than all these issues is the philosophical import of the new knowledge. Hidden inside the genome are thousands of genes, and
millions of non-gene stretches of DNA, each of which tells a secret about the past, the present or the future.

There are genes that tell us what the first creatures on earth looked like more than three billion years ago. There are genes that tell us how our brains are
equipped to produce grammatical language, one of the key distinguishing features of being human. There are genes that tell us about the body plan of an animal
that lived 600 million years ago - the common ancestor of people and fruit flies. There are genes that tell us which of our ancestors took up dairy farming and
when. There are genes that tell us how rapidly we will age. There are genes that tell us which infectious diseases our recent ancestors suffered from.

Above all, there are genes that promise to solve old mysteries of determinism and free will. Are our actions determined by what happened to us a few minutes
ago (behaviourism), by what our parents did to us a few decades ago (psychoanalysis), by what our ancestors did a few hundred thousand years ago
(evolutionary psychology) or by random chance? The answer to such a question has eluded the greatest philosophical minds for centuries. It will never be
settled for certain, but the new insights that can be gathered from the genome will transform it forever.

For example, we already know of 17 human genes, expressed in the brain, whose job is to lay down new memories by the creation of new connections
between brain cells. Those genes are at the mercy of our behaviour, so they do not determine that behaviour as much as result from it. Yet in acting they affect
our future behaviour, too. That is why we experience the genuine sensation of free will, while not being random beings.

These are just a very few of the many insights drawn from the few genes discovered and studied in the late 1990s. Now - this month - thanks to the efforts of
the Human Genome Project, there will be a thousand times as many stories to tell. To paraphrase Sir Edward Grey, the lights are coming on all over biology.

Matt Ridley is the author of: Genome: The autobiography of a species in 23 chapters

YES - it is overhyped - STEVE JONES

"Sulston essentially called us a fraud. It's like he's been bit by a rabid animal." Thus, in this week's New Yorker, Craig Venter (head of Celera
Genomics, the privately funded attempt to sequence human DNA) on the director of the British laboratory involved in the public attempt to do the same
job.

Why such bitterness? For Venter, it's C.A.S.H.; but most of the public fuss has to do with the four letters most associated with the announcement of the
(more or less) complete gene sequence, which are H.Y.P. and E.

The four real letters of the code will, hyperbolists tell us, revolutionise biology, medicine and our view of ourselves. Really? Here's a bit of real code:
AACCGGCAG. That's the start of a sequence of DNA unique to the human brain; one of the tiny proportion of our genes not also found in chimps.
Within it, apparently, is written part of what it means to be human. Recite those letters, roll them around the tongue. Feel different, any new philosophical
insights? Of course not: there is more to life than chemistry.

But what about medicine? Genes are certainly important. If you are reading this article on a train, glance at the person to your left and to your right.
Then, comfort yourself with the knowledge that two of the three of you will die as a result of your genes. Should that be unwelcome, it is worth
remembering that a century ago (and depending on the age of your companions) two of the three of you would be dead already.

In Mendel's day, mortality came from outside: from starvation, infection, or cold. Now, things are different. We face the enemy within; our innate failings,
central as they are to ailments such as heart disease, diabetes or cancer. As a result, most people nowadays die of a genetic disease (although not many
notice).

Why, then, am I dismissive about the human genome project? Don't get me wrong: it is an astonishing piece of research in micro-anatomy; a
breakthrough equivalent to Vesalius's dissection of the heart in 1543. But it is anatomy, not surgery. The first heart transplant, it is worth remembering,
was in 1967.

In biology, it can be hard to match science with technology. The skies over the sequencing labs are darkening with the wings of chickens coming home to
roost. Where, after all the cash and the promises, is the payback? The bad news is: don't expect it for a while - not 400 years, maybe; but in my estimate
nearer 40 than four.

DNA transplants have been just around the corner for the past decade - and that is where they are likely to remain. In spite of all the fuss about gene
therapy there is not a single convincing case in which that treatment given alone has cured a disease (with one possible, very recent, exception).

Recently, someone with cystic fibrosis stood up after one of my talks and said she was optimistic because she would soon be cured by a gene transplant.
Sadly - disgracefully, given the false prospectus peddled by the biotech industry - her hopes are premature. In the United States, "gene-therapy"
laboratories are closing down, and those that remain are much more cautious than they were. Her symptoms can now be treated more successfully than a
decade ago, but that has nothing to do with genetics: it comes from the standard advances of medical technology.

What about the ability to find those at risk and at least to prevent the birth of damaged children? Unfortunately, what should be simple again turns out to
be complicated. Cystic fibrosis follows Mendel's laws, and one British couple in 500 is at risk of having an affected child. The human gene sequence must,
surely, give certainty to those in doubt about the risks of this and other diseases.

However, the gene can be damaged in many ways. Every population - sometimes, every family - may have its own mutation. A test that detects an error in
one does not work for others. More than a thousand different CF mutations are known. One causes most of the cases in Western Europe, but in the
Middle East is found in just a small proportion of patients. One illness, an alteration in a single gene, has, it transpires, a multiplicity of causes.

That problem is spectacularly worse for the many common diseases with an inherited component. Such conditions (heart disease, diabetes and the like),
although they run in families, involve many genes that come together each generation in shifting constellations whose effects are hard to predict.

Often, genes are involved in some cases but not in others. For example, one form of heart disease is influenced by a gene that codes for messages sent
from nerves to muscles. However, many others with a weak effect are also involved. Some families, for example, have a tendency towards high blood
cholesterol, but almost 200 different combinations of genes can generate the effect. Risk is also affected by how fat a person is (which itself has an inborn
element). Most people with the illness have drawn an unlucky hand of several low-value DNA cards. Together they increase the danger but any one is of
little use in prediction, let alone treatment.

In fact, such families are easier to identify with a simple blood-cholesterol test than with the most complicated DNA technology. And, of course, the
outside world is also much involved. If everyone ate the Scottish diet, heart disease would be (more or less) a genetic disease. As a result, to ban
cheeseburgers and cigarettes would do more to reduce mortality than anything molecular biology can ever do. Ironically enough, one major contribution
of the genome project has been to emphasise the importance of the environment.

In fact the most dangerous three-letter word in our science is "for": geneticists (unlike the public) known that to find a gene "for" - say - schizophrenia
or heart disease means much less than it seems. Now all that remains is to admit to the subject's four-letter problems and to how little of any practical
value that the gene-sequencers have actually achieved.

Steve Jones is Professor of Genetics at University College, London

The Daily Telegraph